title: [Bisphosphonates in osteoporosis therapy. Standards and perspectives].
abstract: Bisphosphonates are potent inhibitors of bone resorption and approved agents for both the prevention and treatment of osteoporosis. Many clinical studies have shown a consistent reduction in the risk of vertebral fractures with the use of these drugs, while others have shown a clear reduction in the risk of hip and other non-vertebral fractures. The bisphosphonates are divided into three generations based on their potency and chemical structure. In general, as a substance group they are well tolerated and, when applied correctly, the toxicity is low. Alternative dosages, e.g. monthly, three times a month or yearly as an oral drug or i.v. would probably improve patient compliance. Clinical studies have also shown the safety and effectiveness of bisphosphonates over a period of 3-7 years.
authors.affiliation: Ortopädische Praxis am Fürstenhof, Frankfurt.
authors.forename: S
authors.initials: S
authors.lastname: Reinsdorf
authors.forename: B
authors.initials: B
authors.lastname: Habermann
authors.forename: K
authors.initials: K
authors.lastname: Hochmuth
authors.forename: A A
authors.initials: AA
authors.lastname: Kurth
mesh_terms: D000284:Administration, Oral; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001862:Bone Resorption / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D007262:Infusions, Intravenous; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D016103:Spinal Fractures / Q000517:prevention & control; D013329:Structure-Activity Relationship
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates